Assets Under Advice | Fees for 3years | |
35 lacs to 99 lacs | 3% + GST | |
1 Cr to 2.99 Cr | 2.5% + GST | |
3 Cr to 9.99 Cr | 2% + GST | |
10 Cr + | Customised Fees | |
GST @ 18% | ||
|
Please contact us for details | ||
|
An experimental malaria drug developed by Ranbaxy Laboratories Ltd. was effective and safe in a mid-stage clinical trial, according to a study that suggests the treatment may offer an alternative to current medicines. Among 230 people with the deadliest form of malaria in Thailand, India and Tanzania, Ranbaxy’s arterolane cleared the disease in as many as 72 percent of patients within 28 days.
Malaria strikes about 250 million people each year and kills more than 880,000, mostly children under 5 in Africa, according to the World Health Organization. It’s the world’s third-deadliest infectious disease, with only AIDS, which results in about 2 million deaths each year, and tuberculosis, which kills 1.6 million people annually, according to WHO.
A study published in the New England Journal of Medicine last year showed drugs derived from artemisinin took almost twice as long to clear the parasites that cause the disease in patients in western Cambodia as in patients in northwestern Thailand. Ranbaxy is now studying arterolane in combination with an older drug, piperaquine, in a late-stage patient study in India, Bangladesh and Thailand.
crackcrackCompany Name | CMP |
---|---|
Sun Pharma Inds. | 1705.15 |
Dr. Reddys Lab | 1155.80 |
Cipla | 1481.40 |
Lupin | 2012.05 |
Zydus Lifesciences | 884.20 |
View more.. |